Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
Community Ventures is a non-profit organization that fosters local community econo...
Community Ventures is a non-profit organization...
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the ...
Motus GI Holdings, Inc. is a medical technology...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicat...
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI...
Cancer is one of the most difficult diseases to treat. It is constantly changing, ...
Cancer is one of the most difficult diseases to...
TCR² is an innovative immunotherapy company developing the next generation of T c...
TCR² is an innovative immunotherapy company de...
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...
BioCryst Pharmaceuticals discovers novel, oral ...
Join the National Investor Network and get the latest information with your interests in mind.